ALK and non-small cell lung carcinoma: These results suggest that lorlatinib has a relatively favorable efficacy profile compared to other existing ALK inhibitors, and support the possibility that lorlatinib may be a potential new first-line treatment option for ALK-p advanced NSCLC.